During Monday’s current trade, Athersys, Inc. (NASDAQ:ATHX)’s shares declined -1.43% to $1.38, after a biotechnology company, hit a one-year low of 90 cents on Friday after the biotech company’s stem-cell therapy to treat strokes failed a mid-stage study.
The therapy called MultiStem, which was company’s only product to reach human trials, failed a mid-stage trial that tested it as a treatment for ischemic strokes, which account for about 87% of all stroke cases.
The study tested the safety and efficacy of the treatment when given between 24 and 48 hours after an ischemic stroke. The data showed that MultiStem was not better than a placebo when given after 36 hours, but it also demonstrated that the therapy had better efficacy when given before 36 hours.
“Unfortunately, we just didn’t have the window right for this study,” Athersys COO William Lehmann told Reuters. “We believe investors should see this as a sign that MultiStem works.”
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has accomplished Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-as compared to-host disease.
During an afternoon trade, Verizon Communications Inc. (NYSE:VZ)’s shares inclined 0.49% to $49.14.
Verizon Wireless, a technology leader with the nation’s largest and most reliable 4G LTE network, has beefed up its network at Churchill Downs with new “small cell” technology and other upgrades to handle the burgeoning traffic generated by the hundreds of thousands of Derby week guests who want to share messages, photos and videos via their wireless devices. On Derby day 2014, 4G LTE traffic on the Verizon Wireless network raised 224 percent over Derby day 2013, and Verizon customers consumed 1.37 terabytes of data.
Verizon has installed nearly a dozen small cells around Churchill Downs to expand the capacity of existing Verizon cells sites near the grounds. Verizon also will deploy mobile assets in 2015 counting a COW or “cell on wheels,” and a COLT or “cell on light truck.” In addition, Verizon added XLTE capacity – which utilizes Verizon’s AWS (Advanced Wireless Services) spectrum to deliver faster peak speeds and at least double the bandwidth to 4G LTE customers.
In 2014, Verizon collaborated with Mobilitie to deploy a Distributed Antenna System (DAS) at Churchill Downs. This year the DAS will receive additional upgrades, counting 21 new antennas to improve coverage and balance traffic.
Verizon Wireless operates the nation’s largest and most reliable 4G LTE network. As the largest wireless company in the U.S., Verizon Wireless serves 106.2 million retail customers, counting 100.1 million retail postpaid customers. Verizon Wireless is wholly owned by Verizon Communications Inc. (VZ).
Verizon Communications Inc., through its auxiliaries, provides communications, information, and entertainment products and services to consumers, businesses, and governmental agencies worldwide.
AbbVie Inc. (NYSE:ABBV), during its Monday’s current trading session gained 2.01%, to $63.54.
AbbVie, declared that it has extended the expiration of its exchange offer to attain all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 1, 2015.
On April 17, 2015, AbbVie also voluntarily withdrew its initial Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act in order to provide the FTC with additional time to review the projected transaction. A new 30 calendar day HSR waiting period will start when AbbVie resubmits its HSR filing, which is predictable to occur on April 21, 2015. AbbVie and Pharmacyclics continue to work cooperatively with the Federal Trade Commission staff in their review of the projected transaction, and expect to close the transaction in second-quarter 2015.
The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on April 17, 2015, a total of about 47,465,978 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer.
All other terms and conditions of the exchange offer remain unchanged.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases.
Finally, Mondelez International, Inc. (NASDAQ:MDLZ), lost -0.04% Monday.
Mondelez International, will release its first quarter 2015 financial results on Wednesday, April 29, at 8 a.m. EDT and will host a conference call at 10 a.m. EDT that day.
Mondelez International, Inc., through its auxiliaries, manufactures and markets snack food and beverage products worldwide. The company offers biscuits, counting cookies, crackers, and salted snacks; chocolates, and gums and candies; powdered beverages and coffee; and cheese and grocery products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
